Interneuron disputes Johns Hopkins study

Interneuron Pharmaceuticals Inc. quickly sought to diffuse the impact of an animal study critical of the company's anti-obesity drug dexfenfluramine that was published last week by researchers at Johns Hopkins University and the National Institute on Drug Abuse.

Dexfenfluramine is believed to act on nerve cells containing the messenger serotonin, by mimicking the serotonin signal